# Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

> **NCT01155817** · PHASE1 · COMPLETED · sponsor: **Stanford University** · enrollment: 33 (actual)

## Conditions studied

- Bone Marrow Transplant Failure
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell, Peripheral

## Interventions

- **DRUG:** Nilotinib

## Key facts

- **NCT ID:** NCT01155817
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2020-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01155817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01155817, "Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01155817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*